United States: Global Dossier: Update - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Mondaq

23 Oct 2023 0 shares 1 views

United States: Global Dossier: Update - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Mondaq

Published 23 Oct 2023

Global Dossier is a joint project between the IP5 Offices. The IP5 Offices include the European Patent Office (EPO), Japan Patent Office (JPO), Korean Intellectual Property Office (KIPO)...

Full Article

United States: Substitute Claims Upheld As Prior Art Is Inapplicable To Pharmaceutical Compositions - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Mondaq 31 Oct 2023

In Hope Medical Enterprises Inc., v. Fennec Pharmaceuticals Inc.,[i] the Board's Final Written Decision (FWD) found that Petitioner..

More coverage

United States: Characterization Of Reference As Primary Or Secondary Has No Effect On The Obviousness Analysis - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Mondaq 23 Oct 2023

In Schwendimann v. Neenah, Inc., No. 22-1333 (Fed. Cir. Oct. 6, 2023), the Federal Circuit affirmed the Patent Trial and Appeal..

United States: Global Dossier: Update - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

United States: Global Dossier: Update - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

You might like

Related news coverage

United States: Substitute Claims Upheld As Prior Art Is Inapplicable To Pharmaceutical Compositions - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Advertisement

More coverage

United States: Characterization Of Reference As Primary Or Secondary Has No Effect On The Obviousness Analysis - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP